Yale University and Genaissance Pharmaceuticals Co-Sponsor Conference on Pharmacogenetics: Drug Development and Regulation in the Age of Genomics - A Pathway to Personalized Medicine
NEW HAVEN, Conn., April 16 /PRNewswire-FirstCall/ -- Yale University School of Medicine and Genaissance Pharmaceuticals, Inc. invite you to attend the Sixth Annual Pharmacogenetics and Medicine Lectures: Drug Development and Regulation in the Age of Genomics on Friday, April 25th 2003 from 8:00 AM -- 1:00 PM at the Congress Avenue Building, Yale University School of Medicine, New Haven, CT 06510.
Recent announcements by the FDA ("Improving Innovation in Medical Technology: Beyond 2002 -- fda.gov, have demonstrated the agency's intent of taking a more active role in education and guideline development in the field of pharmacogenomics.
"The pharmaceutical and biotechnology industries are eagerly anticipating the FDA's direction in pharmacogenomics since it will profoundly influence how medicines will be developed and marketed," said Gualberto Ruano, M.D., Ph.D., Vice Chairman and Chief Scientific Officer of Genaissance Pharmaceuticals. "We are honored that two of the FDA's leaders, Drs. Janet Woodcock and Lawrence Lesko, have agreed to share their regulatory insights on this emerging field at this symposium." The agenda will also feature other prominent experts highlighting new directions for pharmacogenomics beginning with the molecular understanding of disease and extending to new applications in nutrition, bio-defense and forensic medicine.
Symposium speakers on April 25th include:
* Janet Woodcock, M.D., Director, Center for Drug Evaluation and
Research, Food and Drug Administration.
Drug Development and Regulation in the Age of Pharmacogenomics
* William Wallen, Ph.D., Senior Vice President, Research and Development,
Bayer Diagnostics.
Drug Response, Optimization and Trends in Individualized Patient
Management
* Stefan Somlo, M.D., Chief, Section of Nephrology and Professor,
Internal Medicine and Genetics, Yale University School of Medicine,
Boyer Center for Molecular Medicine
The Genetics of Renal Disease: The Potential for Personalized Therapy
in the Future
* Linda M. Bartoshuk, Ph.D., Professor, Department of Surgery,
Otolaryngology, Yale University School of Medicine
Genetic Variation in Taste Leads to Variation in Diet and Health Risks
* Steven H. Wong, M.D., Professor, Pathology and Director, Clinical
Toxicology, Therapeutic Drug Monitoring and Pharmacogenetics, Medical
College of Wisconsin
Pharmacogenomics: A New Approach for Autopsy in Forensic Medicine
* Gualberto Ruano, M.D., Ph.D., Vice Chairman and Chief Scientific
Officer, Genaissance Pharmaceuticals, Inc.,
Genomic Signatures of Survival in Adverse Environments: A Platform for
Bio-Defense
* Lawrence Lesko, Ph.D., Director, Office of Clinical Pharmacology and
Biopharmaceutics, Food and Drug Administration
Drug Monitoring with Genetics: A Regulatory Perspective
For program details and to register go to www.genaissance.com/enews
Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of human gene variation for the development of personalized medicines. The Company markets its technology and clinical development skills to the pharmaceutical industry as a complete solution for improving the development, marketing and prescribing of drugs. Genaissance has agreements with eight major pharmaceutical, diagnostic and biotechnology companies: AstraZeneca, Bayer, BD (Becton, Dickinson and Company), Biogen, Johnson & Johnson PRD, Millennium, Pfizer and Pharmacia. Genaissance is located in Science Park in New Haven, Connecticut. |
